Schear Investment Advisers LLC Acquires 704 Shares of Novo Nordisk A/S (NYSE:NVO)

Schear Investment Advisers LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 12.2% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 6,463 shares of the company’s stock after acquiring an additional 704 shares during the period. Schear Investment Advisers LLC’s holdings in Novo Nordisk A/S were worth $770,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in NVO. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S during the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter worth $25,000. Gilliland Jeter Wealth Management LLC boosted its stake in shares of Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares during the last quarter. Halpern Financial Inc. increased its position in Novo Nordisk A/S by 113.0% during the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. Finally, Abound Wealth Management lifted its holdings in Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after acquiring an additional 157 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 3.4 %

Novo Nordisk A/S stock opened at $101.74 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The firm has a market capitalization of $456.56 billion, a price-to-earnings ratio of 32.93, a P/E/G ratio of 1.31 and a beta of 0.42. The firm has a 50 day moving average of $118.58 and a 200 day moving average of $129.59.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on NVO shares. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.